Fluorescence detection of tramadol in healthy Chinese volunteers by high-performance liquid chromatography and bioequivalence assessment

Xiao Zhou, Ji Liu, Xiao Zhou, Ji Liu

Abstract

This study developed a revised high-performance liquid chromatography fluorescence method to determine plasma tramadol concentration, and thereby to examine the bioequivalence of two tramadol formulations among healthy male Chinese volunteers. The study used a double-blind, randomized, 2×2 crossover-design principle. Calculated pharmacokinetic parameters for both formulations were consistent with previous reports. According to the observation of vital signs and laboratory measurement, no subjects had any adverse reactions. The geometric mean ratios (90% confidence interval) of the test drug/reference drug for tramadol were 100.2% (95.3%-103.4%) for the area under the plasma concentration-time curve (AUC) from time zero to the last measurable concentration, 99.6% (94.2%-102.7%) for the AUC from administration to infinite time, and 100.8% (93.1%-106.4%) for maximum concentration. For the 90% confidence intervals of the test/reference AUC ratio and maximum concentration ratio of tramadol, both were in the acceptance range for bioequivalence. According to the two preparations by pharmacokinetic parameter statistics, the half-life, mean residence time, and clearance values showed no significant statistical differences. Therefore, the conclusion of this study was that the two tramadol formulations (tablets and capsules) were bioequivalent.

Keywords: bioequivalence; fluorescence detector; in vitro release; pharmacokinetic; tramadol hydrochloride.

Figures

Figure 1
Figure 1
Chromatograms of tramadol in plasma. Notes: (A) Blank plasma; (B) standard plasma sample; (C) plasma sample after dosing. 1, Tramadol; 2, internal standard; 3, O-desmethyltramadol.
Figure 2
Figure 2
In vitro release profiles of tramadol from the test and reference (50 mg). Notes: ⋄, Tablets; △, capsules. Release experiments were carried out in 0.1 M (HCL solution), at 37°C±0.5°C. Each point represents the mean value of six different experiments ± standard deviation.
Figure 3
Figure 3
Mean plasma concentration–time profiles of tramadol from the test and reference in healthy male Chinese volunteers (50 mg). Note: Each profile represents the mean ± standard deviation of ten volunteers.

References

    1. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923.
    1. Wu WN, McKown LA, Liao S. Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica. 2002;32(5):411–425.
    1. García Quetglas E, Azanza JR, Cardenas E, Sádaba B, Campanero MA. Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol. Biopharm Drug Dispos. 2007;28(1):19–33.
    1. Subrahmanyam V, Renwick AB, Walters DG, et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos. 2001;29(8):1146–1155.
    1. Zydol SR [prescribing information] Wycombe, UK: Grunenthal; 2010.
    1. Ultram ER [prescribing information] Steinbach, MB: Biovail; 2010.
    1. Qu L, Feng S, Wu Y, Wu Y. HPLC method for determination of tramadol hydrochloride in human plasma. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003;34(3):574–575. Chinese.
    1. Gan SH, Ismail R, Wan Adnan WA, Wan Z. Method development and validation of a high-performance liquid chromatographic method for tramadol in human plasma using liquid-liquid extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;772(1):123–129.
    1. Ebrahimzadeh H, Yamini Y, Sedighi A, Rouini MR. Determination of tramadol in human plasma and urine samples using liquid phase microextraction with back extraction combined with high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;863(2):229–234.
    1. Küçük A, Kadioğlu Y, Celebi F. Investigation of the pharmacokinetics and determination of tramadol in rabbit plasma by a high-performance liquid chromatography-diode array detector method using liquid-liquid extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;816(1–2):203–208.
    1. Ho ST, Wan JJ, Liaw WJ, Ho CM, Li JH. Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. J Chromatogr B Biomed Sci Appl. 1999;736(1–2):89–96.
    1. Gambaro V, Benvenuti C, De Ferrari L, Dell’Acqua L, Farè F. Validation of a GC/MS method for the determination of tramadol in human plasma after intravenous bolus. Farmaco. 2003;58(9):947–950.
    1. Leis HJ, Fauler G, Windischhofer W. Synthesis of d1-N-ethyltramadol as an internal standard for the quantitative determination of tramadol in human plasma by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;804(2):369–374.
    1. Sha YF, Shen S, Duan GL. Rapid determination of tramadol in human plasma by headspace solid-phase microextraction and capillary gas chromatography-mass spectrometry. J Pharm Biomed Anal. 2005;37(1):143–147.
    1. Center for Drug Evaluation . The Guiding Principle of Bioavailability of China. Beijing: State Food and Drug Administration; 2006.
    1. Prior A, Frutos P, Correa CP. Comparison of dissolution profiles: current guidelines. [Accessed November 1, 2010]. Available from: .
    1. World Medical Association . World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire, France: WMA; 2008. [Accessed January 7, 2015]. Available from: .
    1. De Leo M, Giorgi M, Saccomanni G, Manera C, Braca A. Evaluation of tramadol and its main metabolites in horse plasma by high-performance liquid chromatography/fluorescence and liquid chromatography/electrospray ionization tandem mass spectrometry techniques. Rapid Commun Mass Spectrom. 2009;23(2):228–236.
    1. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15(6):657–680.
    1. García-Quetglas E, Azanza JR, Sádaba B, Muñoz MJ, Gil I, Campanero MA. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res. 2007;55(2):122–130.
    1. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300(21):2514–2526.

Source: PubMed

3
Tilaa